Pituitary Tumors
Pituitary tumors account for approximately 15% of all intracranial neoplasms and are the third most common primary intracranial tumor after meningiomas and gliomas. The 2022 WHO Classification of Endocrine and Neuroendocrine Tumors introduced the term pituitary neuroendocrine tumor (PitNET) to replace the traditional designation “pituitary adenoma,” reflecting the neuroendocrine lineage of these neoplasms and aligning nomenclature with neuroendocrine tumors elsewhere in the body. While the vast majority of PitNETs are benign, they cause significant morbidity through hormonal hypersecretion, mass effect on adjacent structures — particularly the optic chiasm and cavernous sinuses — and the risk of acute pituitary apoplexy. Neurologists frequently encounter these tumors in the evaluation of visual field deficits, headache, cranial neuropathies, and endocrine dysfunction.
Bottom Line
- Terminology: The WHO 2022 classification replaces “pituitary adenoma” with pituitary neuroendocrine tumor (PitNET), emphasizing neuroendocrine origin
- Classification: Microadenoma (<10 mm) vs macroadenoma (≥10 mm); functional (hormone-secreting) vs nonfunctional (clinically silent)
- Most common functional type: Prolactinoma (~40% of all PitNETs), treated medically with dopamine agonists — even giant prolactinomas respond to cabergoline
- Neurologic manifestations: Bitemporal hemianopia (chiasmal compression), headache, cranial nerve palsies (CN III, IV, V1, V2, VI via cavernous sinus invasion), pituitary apoplexy
- Pituitary apoplexy: Neurosurgical emergency — acute hemorrhage or infarction presenting with thunderclap headache, visual loss, ophthalmoplegia, and acute hypopituitarism
- Workup: MRI sella with dynamic contrast, complete pituitary hormone panel, formal visual field testing (Humphrey perimetry)
- Treatment principle: Prolactinomas are treated medically first; nonfunctional macroadenomas and GH/ACTH-secreting tumors are treated surgically (transsphenoidal approach)
Classification and Nomenclature
WHO 2022 Update: Pituitary Neuroendocrine Tumors (PitNETs)
The reclassification from “adenoma” to PitNET was driven by several considerations: (1) pituitary tumors arise from neuroendocrine cells of the anterior pituitary and share lineage markers (synaptophysin, chromogranin) with neuroendocrine tumors in other organs; (2) the term “adenoma” implies uniformly benign behavior, which is misleading for aggressive PitNETs that invade surrounding structures; and (3) alignment with WHO classification of neuroendocrine tumors elsewhere. The new classification system classifies PitNETs by pituitary transcription factor lineage (PIT1, TPIT, SF1) rather than solely by immunohistochemical hormone staining.
| Transcription Factor Lineage | Cell Type | Tumor Type | Hormone Produced |
|---|---|---|---|
| PIT1 lineage | Somatotroph | GH-secreting PitNET | Growth hormone (GH) |
| Lactotroph | Prolactinoma | Prolactin (PRL) | |
| Thyrotroph | TSH-secreting PitNET | Thyroid-stimulating hormone (TSH) | |
| TPIT lineage | Corticotroph | ACTH-secreting PitNET | Adrenocorticotropic hormone (ACTH) |
| SF1 lineage | Gonadotroph | Gonadotroph PitNET (usually nonfunctional) | FSH, LH (often clinically silent) |
| No lineage | Null cell | Null cell PitNET | None |
Size-Based Classification
| Category | Size | Clinical Significance |
|---|---|---|
| Microadenoma | <10 mm | Usually incidental or presents with hormonal symptoms; rarely causes mass effect |
| Macroadenoma | ≥10 mm | Significant mass effect risk; suprasellar extension → chiasmal compression |
| Giant PitNET | ≥40 mm | Extensive invasion; often requires multimodal treatment; higher surgical morbidity |
Functional Classification
| Functional Type | Frequency | Clinical Syndrome | Key Diagnostic Test |
|---|---|---|---|
| Prolactinoma | ~40% | Amenorrhea, galactorrhea, hypogonadism, infertility, decreased libido | Serum prolactin (usually >200 ng/mL for macroadenoma; correlates with tumor size) |
| Nonfunctional | ~30% | Mass effect symptoms only (visual field loss, headache, hypopituitarism) | No elevated hormone; mild PRL elevation (<100 ng/mL) may reflect stalk effect |
| GH-secreting | ~15% | Acromegaly (adults): coarsened features, acral enlargement, OSA, cardiomyopathy, diabetes | Elevated IGF-1; GH not suppressed by oral glucose tolerance test (OGTT) |
| ACTH-secreting | ~10% | Cushing disease: central obesity, striae, proximal myopathy, hypertension, diabetes, osteoporosis | 24-hour urinary free cortisol, late-night salivary cortisol, dexamethasone suppression test |
| TSH-secreting | <1% | Central hyperthyroidism: elevated free T4 with inappropriately normal/elevated TSH | Elevated free T4 + non-suppressed TSH; elevated alpha-subunit |
Stalk Effect vs Prolactinoma
- A nonfunctional macroadenoma compressing the pituitary stalk can cause mild prolactin elevation (<100–150 ng/mL) by disrupting dopamine inhibition of lactotrophs — this is the “stalk effect”
- Prolactin >200 ng/mL with a macroadenoma is virtually diagnostic of a prolactinoma; levels generally correlate with tumor size
- Misidentifying a prolactinoma as a nonfunctional adenoma leads to unnecessary surgery; misidentifying a nonfunctional adenoma with stalk effect as a prolactinoma leads to futile dopamine agonist therapy
- Hook effect: Very large prolactinomas may produce falsely low prolactin levels on immunoassay due to antibody saturation; request serial dilutions if a giant PitNET has only mildly elevated prolactin
Neurologic Manifestations
Visual Field Deficits
The optic chiasm lies directly above the pituitary gland, separated only by the diaphragma sellae. Suprasellar extension of a PitNET compresses the chiasm from below, characteristically affecting the crossing nasal fibers:
- Bitemporal hemianopia: The classic finding; begins as a superior temporal quadrantanopia and progresses to a complete bitemporal defect
- Junctional scotoma: Compression at the junction of the optic nerve and chiasm produces an ipsilateral central scotoma and a contralateral superior temporal defect (due to Wilbrand knee fibers)
- Homonymous hemianopia: Uncommon; occurs with lateral extension compressing the optic tract
- Optic atrophy: Chronic compression leads to pallor of the optic disc, particularly the temporal portion (band atrophy)
- Visual acuity may be preserved until late stages because the papillomacular bundle is relatively resistant to compression from below
Key Points on Visual Assessment
- Formal Humphrey visual field testing (automated perimetry) is essential at diagnosis and for monitoring
- Optical coherence tomography (OCT) of the retinal nerve fiber layer (RNFL) quantifies axonal loss and may detect subclinical damage before perimetry changes
- Visual field deficits are often the presenting symptom of nonfunctional macroadenomas (which lack hormonal symptoms to prompt earlier detection)
- Chiasmal syndrome from a PitNET is one of the most common causes of bitemporal hemianopia
- Recovery of visual function after decompression is possible if optic nerve axons are still viable (no severe atrophy)
Headache
- Occurs in 40–70% of patients with PitNETs
- Mechanism is multifactorial: dural stretch, cavernous sinus invasion, tumor expansion within the confined sella
- Headache severity does not correlate reliably with tumor size — microadenomas can cause significant headache
- May mimic primary headache disorders (migraine, tension-type); consider pituitary imaging when headache is accompanied by visual or endocrine symptoms
Cranial Neuropathies (Cavernous Sinus Invasion)
Lateral extension of a PitNET into the cavernous sinus can compress cranial nerves traversing this compartment:
| Cranial Nerve | Location in Cavernous Sinus | Clinical Manifestation |
|---|---|---|
| CN III (oculomotor) | Lateral wall (superior) | Ptosis, adduction/elevation deficit, pupil dilation |
| CN IV (trochlear) | Lateral wall | Vertical diplopia (worse looking down and inward) |
| CN V1 (ophthalmic) | Lateral wall | Forehead/periorbital numbness |
| CN V2 (maxillary) | Lateral wall (inferior) | Midface numbness |
| CN VI (abducens) | Free within sinus (medial) | Lateral gaze palsy; most commonly affected due to its vulnerable position |
Hypopituitarism
Compression of normal pituitary tissue by a growing PitNET leads to progressive hormone deficiency, typically in a predictable order:
- GH deficiency (earliest — often subclinical in adults)
- Gonadotropins (FSH/LH) → hypogonadism
- TSH → central hypothyroidism
- ACTH → secondary adrenal insufficiency (most dangerous; last to be lost under gradual compression)
Pituitary Apoplexy
Pituitary apoplexy is an acute clinical syndrome caused by hemorrhage or infarction of a pituitary tumor, most commonly a macroadenoma. It represents a neurosurgical and endocrinologic emergency.
Red Flags — Pituitary Apoplexy
- Presentation: Sudden severe headache (often “thunderclap”), nausea/vomiting, visual loss, ophthalmoplegia, altered mental status, meningismus
- Precipitants: Anticoagulation, coagulopathy, pregnancy, dopamine agonist withdrawal, major surgery, dynamic pituitary testing, bromocriptine initiation (rare)
- Mimics: Subarachnoid hemorrhage, bacterial meningitis, cavernous sinus thrombosis, migraine
- Acute adrenal crisis: Life-threatening hypocortisolism requiring immediate IV hydrocortisone (100 mg bolus, then 50 mg every 8 hours) — treat empirically before lab confirmation
- Imaging: CT may show hyperintense sellar mass (hemorrhage); MRI is superior for delineating hemorrhage (T1 hyperintensity) and ischemia
Management of Pituitary Apoplexy
| Scenario | Management | Rationale |
|---|---|---|
| Severe visual loss or deteriorating vision | Urgent transsphenoidal surgery (within 24–72 hours) | Decompression of the chiasm offers best chance of visual recovery |
| Isolated ophthalmoplegia without visual loss | Conservative management with close monitoring | Cranial nerve palsies from cavernous sinus compression often resolve spontaneously |
| Diminished consciousness | Emergent surgery + ICU admission | May indicate hydrocephalus, hypothalamic compression, or severe adrenal crisis |
| All cases | Immediate corticosteroid replacement (IV hydrocortisone) | Acute hypopituitarism with adrenal crisis is the most immediate life-threatening complication |
Diagnostic Workup
Imaging
- MRI of the sella with dynamic contrast: Gold standard; thin coronal and sagittal cuts through the sella; dynamic sequences (rapid sequential images during contrast injection) detect microadenomas that enhance later than normal pituitary tissue
- CT sella: Inferior to MRI but useful in acute apoplexy to identify hemorrhage; also shows bony erosion of the sellar floor
- Incidental pituitary findings: “Pituitary incidentalomas” are found on 10–20% of brain MRIs; most are small, nonfunctional, and clinically insignificant
Knosp Classification for Cavernous Sinus Invasion
The Knosp grading system uses coronal MRI to assess the relationship of the PitNET to the internal carotid artery (ICA) and predict cavernous sinus invasion:
| Knosp Grade | MRI Finding | Cavernous Sinus Invasion | Surgical Implication |
|---|---|---|---|
| Grade 0 | Tumor does not reach medial tangent of ICA | No invasion | Complete resection usually achievable |
| Grade 1 | Tumor reaches but does not pass medial tangent | No invasion | Complete resection usually achievable |
| Grade 2 | Tumor passes medial tangent but not lateral tangent | Possible invasion | Complete resection may be difficult |
| Grade 3A | Tumor extends lateral to lateral tangent (superior) | Probable invasion | Gross total resection unlikely |
| Grade 3B | Tumor extends lateral to lateral tangent (inferior) | Probable invasion | Gross total resection unlikely |
| Grade 4 | Tumor completely encases ICA | Definite invasion | Complete resection not possible; debulking only |
Endocrine Evaluation
Complete Pituitary Hormone Panel
- Prolactin: Elevated in prolactinomas (correlates with tumor size); mild elevation (<100 ng/mL) suggests stalk effect; request serial dilutions for giant tumors (hook effect)
- IGF-1: Screening for GH excess (acromegaly); if elevated, confirm with OGTT (failure to suppress GH <1 ng/mL)
- Morning cortisol + ACTH: Low cortisol with low/normal ACTH indicates secondary adrenal insufficiency; 24-hour urinary free cortisol and late-night salivary cortisol to screen for Cushing disease
- Free T4 + TSH: Low free T4 with low/inappropriately normal TSH indicates central hypothyroidism; elevated free T4 with non-suppressed TSH suggests TSH-secreting PitNET
- LH, FSH, estradiol/testosterone: Hypogonadotropic hypogonadism common with macroadenomas
- Sodium and serum osmolality: Baseline assessment; diabetes insipidus is uncommon with PitNETs at presentation (more common with craniopharyngiomas, metastases, and postoperatively)
Visual Field Testing
- Humphrey visual field (automated perimetry): Standard for documenting and monitoring visual field deficits
- Goldmann perimetry: Useful for severe deficits or uncooperative patients
- Baseline visual field testing is required for all macroadenomas with suprasellar extension and should be repeated postoperatively and during follow-up
Treatment
Prolactinoma
Prolactinomas are unique among PitNETs in that medical therapy is first-line, regardless of tumor size:
- Cabergoline: Preferred dopamine agonist; dosed 0.25–1 mg twice weekly (titrated to normalize prolactin); superior efficacy and fewer side effects compared with bromocriptine
- Bromocriptine: Alternative; dosed 2.5–15 mg/day; preferred in pregnancy (more safety data)
- Response rate: Prolactin normalization in ~80–90% and significant tumor shrinkage in ~80% of patients on cabergoline, including giant prolactinomas
- Cardiac valvulopathy: High-dose cabergoline (used in Parkinson disease, ≥3 mg/day) carries risk of valvular fibrosis; at lower doses used for prolactinomas, risk is minimal, but echocardiographic monitoring is recommended for doses >2 mg/week
- Surgery indications: Dopamine agonist intolerance or resistance, CSF leak from tumor shrinkage, patient preference
- Temozolomide: Reserved for aggressive, refractory prolactinomas not responding to dopamine agonists or surgery; MGMT promoter methylation status may predict response
Nonfunctional PitNETs
- Observation: Appropriate for incidentalomas <10 mm without mass effect; serial MRI (6 months, then annually) and visual field monitoring
- Surgery: Indicated for visual field compromise, progressive growth, proximity to optic chiasm, or significant hypopituitarism; transsphenoidal approach is standard
- Radiation: Adjuvant stereotactic radiosurgery (Gamma Knife) or fractionated radiotherapy for residual/recurrent tumor not amenable to repeat surgery
GH-Secreting PitNETs (Acromegaly)
- Surgery: First-line (transsphenoidal); biochemical remission (normal IGF-1, GH <1 ng/mL on OGTT) in 80–90% of microadenomas, 40–60% of macroadenomas
- Somatostatin receptor ligands (SRLs): Octreotide LAR, lanreotide — second-line for persistent disease post-surgery; normalize IGF-1 in ~55%
- Pegvisomant: GH receptor antagonist; normalizes IGF-1 in >90% but does not shrink tumor
- Cabergoline: Modest efficacy as adjunctive therapy, especially with mild IGF-1 elevation and co-secretion of prolactin
ACTH-Secreting PitNETs (Cushing Disease)
- Surgery: First-line (transsphenoidal); remission in 70–90% of microadenomas; lower for macroadenomas
- Inferior petrosal sinus sampling (IPSS): Gold standard to confirm pituitary ACTH source (vs ectopic ACTH) when imaging is equivocal; central-to-peripheral ACTH gradient ≥2 (basal) or ≥3 (after CRH stimulation) confirms Cushing disease
- Medical options for persistent disease: Ketoconazole, osilodrostat (11-beta-hydroxylase inhibitor), metyrapone (steroidogenesis inhibitors); pasireotide (somatostatin analog targeting SSTR5); cabergoline
- Bilateral adrenalectomy: Definitive cure of hypercortisolism but causes permanent adrenal insufficiency and risk of Nelson syndrome (ACTH-secreting tumor expansion due to loss of cortisol feedback)
Transsphenoidal Surgery
| Aspect | Details |
|---|---|
| Approach | Endoscopic endonasal transsphenoidal (most common); microscopic sublabial transsphenoidal; transcranial (rare, for giant tumors) |
| Remission rates | Microadenomas: 80–95%; macroadenomas: 50–70% (varies by tumor type and surgeon experience) |
| Complications | Diabetes insipidus (10–20% transient, 1–3% permanent), CSF leak (1–5%), hypopituitarism (new or worsened), epistaxis, meningitis (rare) |
| Volume-outcome relationship | Surgical outcomes strongly correlate with surgeon and center experience; referral to high-volume centers recommended |
Postoperative Complications
Diabetes Insipidus
- Most common postoperative complication; results from damage to the posterior pituitary or pituitary stalk disrupting ADH (vasopressin) secretion
- Classic triad: Polyuria (>3 L/day or >300 mL/hr), polydipsia, dilute urine (osmolality <300 mOsm/kg) with elevated serum sodium
- Transient DI: Occurs in 10–20% of cases; typically resolves within days to weeks
- Permanent DI: 1–3%; requires lifelong desmopressin (DDAVP) replacement
- Triphasic response: DI (days 1–5) → SIADH from unregulated ADH release (days 5–10) → permanent DI (after day 10); hyponatremia during the SIADH phase is a key management risk
Postoperative Hyponatremia
- Occurs in 10–25% of patients after transsphenoidal surgery, typically peaking at days 5–9 postoperatively
- May represent the SIADH phase of the triphasic response or isolated SIADH
- Patients should be instructed to monitor for symptoms (nausea, headache, confusion) and check sodium at 5–7 days postoperatively
- Severe hyponatremia (Na <125 mEq/L) with seizures or altered mental status is a medical emergency requiring hypertonic saline
Hypopituitarism
- New or worsened anterior pituitary hormone deficiency occurs in 5–15% after surgery
- Cortisol deficiency is the most dangerous; morning cortisol should be checked postoperatively before glucocorticoid taper
- Thyroid and gonadal axes should be reassessed at 6–12 weeks postoperatively
- Lifelong hormone replacement may be needed for persistent deficiencies
Special Considerations
Pituitary Incidentalomas
Management of Incidentally Discovered Pituitary Lesions
- Prevalence: Found on ~10–20% of brain MRIs; ~10% of autopsies
- All incidentalomas: Screen for hormonal hypersecretion (prolactin, IGF-1, cortisol) and hypopituitarism
- Microadenomas (<10 mm): If nonfunctional, repeat MRI at 12 months; if stable, no further imaging unless symptoms develop
- Macroadenomas (≥10 mm): Visual field testing; more frequent MRI follow-up (6 months, then annually); consider surgery if close to or compressing the chiasm
- Diabetes insipidus at presentation suggests a diagnosis other than PitNET (consider craniopharyngioma, metastasis, hypophysitis, germ cell tumor)
Aggressive PitNETs and Pituitary Carcinoma
- Aggressive PitNETs: Clinically aggressive behavior with rapid growth, multiple recurrences, and resistance to standard therapies; no single histologic marker is reliable, though elevated Ki-67 (>3%), p53 positivity, and high mitotic count suggest aggressiveness
- Pituitary carcinoma: Defined by craniospinal or systemic metastases; exceedingly rare (<0.2% of PitNETs); most arise from corticotroph or lactotroph tumors
- Temozolomide: Alkylating chemotherapy agent; standard treatment for aggressive PitNETs and pituitary carcinomas; MGMT promoter methylation status correlates with response; 6–12 cycles followed by reassessment
- Immune checkpoint inhibitors: Emerging role in refractory cases; ipilimumab/nivolumab has shown responses in case series
Pituitary Tumors in Pregnancy
- The normal pituitary gland enlarges up to 120–136% during pregnancy due to lactotroph hyperplasia
- Prolactinomas: Microadenomas have <3% risk of clinically significant enlargement; macroadenomas have ~20–30% risk; dopamine agonists (preferably bromocriptine) may be discontinued for microprolactinomas but should be continued for macroprolactinomas
- Acromegaly/Cushing disease: Both pose significant maternal and fetal risks if uncontrolled; management requires multidisciplinary coordination
- MRI (without gadolinium) can be performed if symptomatic enlargement is suspected
Genetic Syndromes
| Syndrome | Gene | Pituitary Tumor Type | Associated Features |
|---|---|---|---|
| MEN1 | MEN1 | Prolactinoma (most common), GH, ACTH | Primary hyperparathyroidism, pancreatic neuroendocrine tumors |
| MEN4 | CDKN1B | Various PitNETs | MEN1-like phenotype without MEN1 mutation |
| Carney complex | PRKAR1A | GH-secreting (acromegaly) | Myxomas, pigmented skin lesions, schwannomas |
| FIPA (AIP-related) | AIP | GH-secreting (young males), prolactinoma | Familial; typically presents in adolescence/young adulthood |
| X-LAG | GPR101 | GH-secreting (gigantism in children) | Very early onset, extreme tall stature |
Differential Diagnosis of Sellar Masses
| Diagnosis | Key Distinguishing Features |
|---|---|
| PitNET | Most common; arises from anterior pituitary; typically enhances homogeneously (except cystic or apoplectic variants) |
| Craniopharyngioma | Calcification (adamantinomatous type), cystic with enhancing solid component, suprasellar > sellar; bimodal age (children + 50–70s) |
| Meningioma | Dural-based, homogeneous enhancement, dural tail sign; arises from planum sphenoidale or tuberculum sellae |
| Rathke cleft cyst | Well-defined, non-enhancing cyst between anterior and posterior lobes; usually incidental |
| Lymphocytic hypophysitis | Diffuse pituitary and stalk enlargement; often peripartum or ICI-related; thickened stalk (“stalkitis”) |
| Pituitary metastasis | Posterior pituitary/stalk involvement (DI common at presentation); breast and lung most common primaries |
| Germ cell tumor | Young patients; thickened stalk; DI; elevated beta-hCG and AFP in serum/CSF |
References
- Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol. 2022;33(1):6-26.
- Melmed S, Kaiser UB, Lopes MB, et al. Clinical biology of the pituitary adenoma. Endocr Rev. 2022;43(6):1003-1037.
- Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317(5):516-524.
- Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65(2):265-273.
- Rajasekaran S, Vanderpump M, Baldeweg S, et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf). 2011;74(1):9-20.
- Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery. 1993;33(4):610-617.
- Dekkers OM, Hammer S, de Keizer RJ, et al. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol. 2007;156(2):217-224.
- Katznelson L, Laws ER, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951.
- Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831.
- Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1-G24.
- Daly AF, Beckers A. The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am. 2020;49(1):21-32.
- Fleseriu M, Hashim IA, Engel N, et al. The role of temozolomide in the treatment of aggressive pituitary tumors and pituitary carcinomas. J Clin Endocrinol Metab. 2022;107(9):2573-2591.